Playlist


Today, citizens of Turkmenistan planning to travel to the Schengen Area—which encompasses 29 European nations—can submit their visa applications through a few key diplomatic missions based in Ashgabat. A Schengen visa grants the holder the right to stay within the zone for up to 90 days within any 180-day period. Currently, direct Schengen visa processing in Ashgabat is managed by the consular sections of the German, Italian, and Romanian embassies, which also legally represent several non-resident European states.
The Embassy of Germany in Ashgabat holds extensive representative authorities, issuing Schengen visas for 14 destinations: Germany, Austria, Belgium, Greece, Estonia, Spain, Latvia, Luxembourg, Malta, the Netherlands, Norway, Portugal, Finland, and Sweden. Additionally, the German mission processes Swiss visas exclusively for holders of diplomatic and service passports. Appointments for document submission must be secured strictly through the embassy’s official online booking system.
The Embassy of Italy in Ashgabat accepts applications for travel to Italy and also processes short-stay Schengen visas (up to 90 days) for France. However, long-stay French national visas must be routed through the VFS Global center in Istanbul. Appointments for the Italian consulate are scheduled free of charge via the Prenot@mi portal. Furthermore, the Embassy of Romania provides direct Schengen visa services in Ashgabat following Romania's accession to the zone in 2024. For other Schengen states, such as Poland, the Czech Republic, Hungary, or Lithuania, regular passport holders must apply through the nearest designated regional consulates located outside Turkmenistan, such as those in Baku or Tashkent.
Also read


Simple Vitamin Shows Surprising Results in Pre-Cancerous Blood Conditions, Study Finds
Today in 02:02Daily high-dose supplementation of vitamin C can significantly reduce mortality risks and help prevent severe medical complications in patients with pre-cancerous blood conditions. Researchers from the Van Andel Institute in the United States and Copenhagen University Hospital in Denmark reached this conclusion following a comprehensive three-year follow-up study. The international "EVITA" trial involved volunteers who were administered 1,000 mg of vitamin C daily over the course of a year, while a control group received a placebo.
Although initial hypotheses suggested vitamin C might directly inhibit abnormal cell proliferation, researchers found its primary benefit lay in strengthening the body, reducing systemic inflammation, and lowering rates of anemia, pneumonia, and internal bleeding. Over the three-year observation period, the vitamin C group exhibited a significantly higher survival rate compared to the placebo group. While experts emphasize that these findings remain preliminary and require larger clinical trials before reshaping formal medical treatment protocols, vitamin C continues to show promising potential in supportive patient care.